

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended). A lipid assembly, being an organized collection of lipids, comprising:

(a) a biologically active non-liposome forming lipid having a hydrophobic region and a polar headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is less than 0.3;

(b) a lipopolymer having a hydrophobic lipid region and a hydrophilic polymer headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is at least 1.5; and

(c) a liposome forming lipid,

the components of the lipid assembly being selected such that the lipid assembly is chemically and physically stable under storage conditions of 4°C in biological fluids, for at least six months.


2 (Previously Presented). The lipid assembly of Claim 1, wherein the assembly has an additive effective packing parameter in the range of 0.74-1.0.

3 (Previously Presented). The lipid assembly of Claim 1, having a level of water tightly bound to said lipopolymer headgroup of at least 60 molecules of water per lipopolymer headgroup.

4 (Cancelled).

5 (Previously Presented). The lipid assembly of Claim 1, wherein said biologically active non-liposome forming lipid is selected from the group consisting of ceramides, ceramines, sphinganines, sphinganine-1-phosphate, di- or tri-alkylshpingosines and their structural analogs.

6 (Previously Presented). The lipid assembly of Claim 5, wherein said biologically active non-liposome forming lipid has the following general formula (I):



wherein

- R_1 represents a $\text{C}_2\text{-C}_{26}$, saturated or unsaturated, branched or unbranched, aliphatic chain, wherein the aliphatic chain may be substituted with one or more hydroxyl or cycloalkyl groups and may consist

of a cycloalkylene moiety;

- R_2 , which may be the same or different, represents a hydrogen, a C_1-C_{26} saturated or unsaturated, branched or unbranched chain selected from the group consisting of an aliphatic chain, an aliphatic carbonyl chain and a cycloalkylene-containing aliphatic chain; wherein the aliphatic chain may be substituted with an aryl, arylalkyl or arylalkenyl group;
- R_3 represents a hydrogen, a methyl, ethyl, ethenyl or a phosphate group.

7 (Previously Presented). The lipid assembly of Claim 6, wherein said biologically active non-liposome forming lipid is a C_2-C_{26} ceramide.

8 (Previously Presented). The lipid assembly of Claim 6, wherein said biologically active non-liposome forming lipid is N,N-dimethylsphingosine (DMS).

9 (Cancelled).

10 (Previously Presented). The lipid assembly of Claim 1, wherein said lipopolymer comprises a polymer headgroup selected from the group consisting of polyethylene glycol (PEG), polysialic acid, polylactic acid, polyglycolic acid, apolylactic-polyglycolic acid, polyvinyl alcohol,

polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline,
polyhydroxyethyloxazoline, polyhydroxypropyloxazoline,
polyaspartamide, polyhydroxypropyl methacrylamide,
polymethacrylamide, polydimethylacrylamide,
polyvinylmethylether, polyhydroxyethyl acrylate, and
derivatized celluloses.

11 (Previously Presented). The lipid assembly of
Claim 10, wherein said polymer headgroup is polyethylene
glycol (PEG) having an atomic mass in the range of about 750
Da to about 20,000 Da.

12 (Cancelled).

13 (Previously Presented). The lipid assembly of
Claim 10, wherein said PEG has an atomic mass of 2,000Da
(2kPEG).

14 (Currently Amended). The lipid assembly of
Claim 1, wherein said liposome forming lipid ~~comprises is a~~
phospholipid.

15 (Cancelled).

16 (Previously Presented). The lipid assembly of
Claim 14, wherein said phospholipid is a glycerophospholipid
selected from the group consisting of phosphatidylglycerol
(PG), phosphatidylcholine (PC), phosphatidic acid (PA),
phosphatidylinositol (PI), phosphatidylserine (PS),

Appln. No. 10/551,649
Amdt. dated September 27, 2010
Reply to Office action of March 26, 2010

sphingomyelin (SPM) and derivatives of the same.

17 (Previously Presented). The lipid assembly of Claim 1, wherein said liposome forming lipid comprises a cationic lipid.

18 (Previously Presented). The lipid assembly of Claim 17, wherein said cationic lipid is a monocationic lipid having a headgroup selected from the group consisting of 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP); 1,2-dioleyloxy-3-(trimethylamino) propane (DOTAP); N-[1-(2,3,-ditetradecyloxy)propyl]-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE); N-[1-(2,3,-dioleyloxy)propyl]-N,N-dimethyl-N-hydroxy ethyl-ammonium bromide (DORIE); N-[1-(2,3-dioleyloxy) propyl]-N,N,N- trimethylammonium chloride (DOTMA); 3 β [N-(N',N'- dimethylaminoethane) carbamoly] cholesterol (DC-Chol); and dimethyl-dioctadecylammonium (DDAB).

19 (Previously Presented). The lipid assembly of Claim 18, wherein said cationic lipid is a polycationic lipid having a headgroup selected from the group consisting of spermine and spermidine.

20 (Original). The lipid assembly of Claim 19, wherein said polycationic lipid is N-[2-[2,5-bis[3-aminopropyl]amino]-1-oxopentyl]amino]ethyl]-N,N-dimethyl-2,3-

Appln. No. 10/551,649
Amdt. dated September 27, 2010
Reply to Office action of March 26, 2010

bis[(1-oxo-9-octadecenyl)oxy]-1-propanaminium (DOSPA) or
ceramide carbamoyl spermine (CCS).

21-25 (Cancelled).

26 (Previously Presented). A pharmaceutical composition comprising a physiologically acceptable carrier and an amount of a lipid assembly in accordance with claim 1, which is sufficient to achieve a biological effect at a target site.

Claims 27-80 (Cancelled).